Evaluating the Quality of Medical Care

Evaluating the Quality of Medical Care

In a Milbank Quarterly Op-Ed, Donald Berwick and Daniel M. Fox put Donabedian’s work into historical perspective.
Read the Op-Ed Read the original article

Recommendations for Strengthening Global Health Security

Strengthening Global Health Security

A Milbank Quarterly study by Lawrence Gostin and Rebecca Katz evaluates the International Health Regulations and offers proposals for reform
Read the study Read the press release

Op-ed Banner

From The Milbank Quarterly

Our Op-Ed section features some of the best minds currently working to improve the public's health. 
Read our op-ed writers

Our Mission

The Milbank Memorial Fund is an endowed operating foundation that works to improve the health of populations by connecting leaders and decision makers with the best available evidence and experience.
Learn about the MMF

A Blueprint for Repair and Renovation of the ACA The Importance of Physicians' Financial Disclosure for the Public's Health A Tale of Two Diseases: Mental Illness and HIV/AIDS Clash of the Titans: State All-Payer Claims Reporting Systems Meet ERISA Preemption Courting Disaster: Environmental Justice and the US Court System Accountability for Health Meeting the ACA's Goals

Addressing High-Cost Pharmaceutical Drugs

June 24, 2016

As the end of the month approaches, so does the end of phase one of SMART-D, the State Medicaid Alternative Reimbursement and Purchasing Test for High-Cost Drugs. A project of the Center for Evidence-based Policy (CEbP) at Oregon Health and Science University, SMART-D is part of a series of grants from the Laura and John Arnold Foundation in Houston, Texas, that address the rising cost of pharmaceutical drugs. SMART-D is aimed at developing a better menu of options for states to consider in purchasing high-cost drugs in Medicaid.

Read more

REPORT: How Can States Support an Aging Population? Actions Policymakers
Can Take

June 8, 2016

It is projected that by 2050, 83.7 million Americans will be over the age of 65, almost double the number who were that age in 2012. During its fall 2015 meetings, the Milbank Memorial Fund’s Reforming States Group turned its attention to the topic, partnering with The New York Academy of Medicine to develop sessions focused on some of the major challenges and opportunities facing states as they look at ways to support an aging population.

The new report, “How Can States Support an Aging Population? Actions Policymakers Can Take,” by Lindsay Goldman and Robert Wolf of the New York Academy of Medicine, provides a review of the issues discussed at the meetings, as well as recommendations for state policy interventions.

Read more

REPORT: Investing in Social Services for States' Health: Identifying and Overcoming the Barriers

May 20, 2016

More and more attention is being paid to the social determinants of health—the conditions in which people are born, grow, work, live, and age, including factors such as income support, education, transportation, and housing—and their contribution to health and well-being. Despite all the evidence about how the factors affecting our health dwarf the impact of the health care we receive, it remains a challenge for state leaders to act. Why don’t state budgets reflect what we know about improving the health of populations? What are examples where, in spite of the barriers, these challenges are being overcome?

This report, written by Elizabeth Bradley, faculty director of the Yale Global Health Leadership Institute, and Erika Rogan, attempts to answer these questions. Based on focused discussions with state and local public health sector leaders, the report identifies the root causes for states not making overall budget and policy decisions that optimize their population’s health.

Read more

Read more news
View From Here

Christopher F. Koller
President of the
Milbank Memorial Fund

Evolving Hepatitis C Drug Coverage Policies: Seeing the Bigger Story

With threats of lawsuits and pressure from government officials, some payers appear to be relaxing their coverage guidelines for expensive direct-acting antiviral drugs (DAAs), including drugs for Hepatitis C. The benefits that increased access to these drugs provide to patients with Hepatitis C—and to the drugs’ manufacturers and investors—will come at the expense of state budgets and, more importantly, broader discussions about matching demand for health care services to limited resources.